Rituximab in hematopoietic cell transplantation

Area of Science:

• Hematopoietic Stem Cell Transplantation
• Immunotherapy
• B Cell Malignancies

Background:

• Rituximab therapy demonstrates significant success in managing B cell malignancies.
• Its application is expanding within both autologous and allogeneic hematopoietic cell transplantation.

Purpose of the Study:

• To review the emerging roles of rituximab in hematopoietic cell transplantation.
• To explore its use in graft purging, maintenance therapy, and conditioning regimens.
• To examine its application in managing chronic graft-versus-host disease and post-transplant lymphoproliferative disorder.

Main Methods:

• Systematic literature search of PubMed for clinical trials involving rituximab and stem cell transplantation.
• Identification and detailed review of 16 relevant clinical trials from an initial pool of 92.
• Focus on studies evaluating rituximab's significance in various transplant contexts.

Main Results:

• Rituximab's utility extends beyond B cell malignancies to other diseases involving B cells.
• The review provides insights into rituximab's application in in vivo graft purging, post-transplant maintenance, and conditioning.
• Understanding of rituximab's role in preventing/treating chronic graft-versus-host disease and post-transplant lymphoproliferative disorder.

Conclusions:

• Rituximab is established in non-transplant therapy for B cell malignancies.
• The challenge lies in optimizing rituximab incorporation for patients with prior exposure undergoing transplantation.
• Further research is needed to address relapse in patients treated with rituximab-containing regimens before transplantation.